Pharma Bloodbath Part VI: The 22,000 layoffs and the 62% Indian hiring surge are the same number, written in two languages.

India isn't growing a pharma sector by spontaneous biological miracle, like algae bloom or a particularly successful Bollywood film about regulatory affairs. India is receiving yours. The 62% Indian hiring surge and the 22,000 Western redundancies aren't separate phenomena. They're the same phenomenon, viewed from the receiving end of a wire transfer.

The story your trade press refuses to name

Every six weeks, the pharma trade press publishes another piece celebrating "India's stunning life sciences growth story" as if a pharmaceutical sector had spontaneously sprouted from the soil of Telangana, like a particularly successful crop of regulatory affairs managers. Tomaten auf den Augen. (Tomatoes on the eyes. Wilful blindness, with garnish.)

Let me say the quiet part out loud, since nobody on your last earnings call wanted to. The pharma jobs disappearing from Basel, Frankfurt and New Jersey are not vanishing. They are being re-hired in Hyderabad, Bengaluru and Pune. The Western layoff column and the Indian hiring column in 2025 are not two stories. They are the same story, told by two different press offices, neither of whom is allowed to mention the other in the same paragraph.

Here is the arithmetic. India now hosts roughly 1,700 to 1,900 operational Global Capability Centres employing around 2.4 million professionals¹. More than 80 of those are dedicated healthcare and life sciences operations. Indian GCCs already manage 45% of global drug discovery and development, 60% of regulatory affairs, and 54% of pharmacovigilance operations for global life sciences firms². Pharma hiring in India surged 62% year on year by March 2025, with pharmacovigilance alone adding roughly 2,200 jobs in twelve months³. Eli Lilly is creating 1,500 positions at its Hyderabad innovation hub. AstraZeneca runs its largest single healthcare GCC globally out of India, with around 4,000 staff and a fresh ₹166 crore expansion adding another 400 roles in 2025⁴. Bristol-Myers Squibb sank $100 million into a 2,000-person Hyderabad operation⁵. Parexel is hiring 2,000 India-based staff in 2025 to absorb clinical work being shifted out of both China and the West.

Meanwhile, on the other side of the ledger: roughly 22,000 Western pharma redundancies have been announced or executed during 2025 alone according to industry layoff trackers⁶, before we even start counting the smaller biotechs. Novo Nordisk: 9,000 cuts, including 5,000 in Denmark⁷. Bayer: a further 2,000 in Q1 2025 on top of 12,000 already eliminated since mid-2023⁸. Merck targeting $3 billion in cost savings through headcount reductions. Bristol-Myers Squibb: roughly 1,000 layoffs in H1 2025 alone. Pfizer: up to 1,702 roles. Novartis: 2,186 gone with up to 8,000 planned. CSL: 15% of its workforce, around 4,500 jobs. Q3 2025 alone clocked 62 separate biopharma layoff rounds in a single quarter⁹.

Two columns. One transaction. Da gibt es nichts zu deuteln. (No room for interpretation there.)

The mechanics, in salary numbers your CFO already memorised

The cost arbitrage runs at 40 to 60% lower per FTE than Western markets on paper. Once you look at the actual numbers role by role, the gap is wider, sometimes much wider. Same job. Same career stage. Wildly different price tag.

Pharmacovigilance specialist. In India, entry-level pay sits at ₹3 to 6 lakh (roughly USD 3,600 to 7,200), rising to ₹16 to 32 lakh (USD 19,000 to 38,000) for senior PV scientists at multinational GCCs¹⁰. Glassdoor pegs the Bangalore average at ₹493,906 (USD 5,900)¹¹. The same role in Germany earns €55,000 to €70,000 (USD 60,000 to 77,000)¹². Switzerland: CHF 90,000 to 110,000 (USD 102,000 to 125,000). United States: $85,000 to $105,000, with seniors past $120,000¹³. In percentage terms: a senior Indian PV scientist takes home roughly 42% of a German peer's package, 25% of a Swiss peer's, and 30% of a US peer's . Put the other way round: Germany costs the employer about 2.4 times what India does, Switzerland 4 times, and the US 3.3 times for equivalent work.

Regulatory affairs manager. Indian average sits at ₹13.75 lakh (USD 16,500), with top earners reaching ₹20 lakh (USD 24,000)¹⁴. Germany averages €108,000 base and €134,000 at senior level¹⁵. Switzerland averages CHF 113,000 and tops out past CHF 175,000¹⁶. Senior US regulatory affairs leadership clears $150,000. In percentage terms: the Indian average is roughly 14% of the German average, 13% of the Swiss, and 11% of the US . Or: Germany costs 7 times, Switzerland 7.7 times, and the US 9 times what India does for the same job title.

Clinical data manager. In India, entry is ₹3 to 12 lakh, with senior CDMs at multinationals reaching ₹20 to 35 lakh (USD 24,000 to 42,000)¹⁷. The same role averages €52,080 in Germany¹⁸, CHF 100,000-plus in Switzerland, and $144,531 in the United States¹⁹. Senior Indian pay sits at roughly 58% of Germany, 29% of Switzerland, and 23% of the United States . Or: Germany costs 1.7 times, Switzerland 3.4 times, the US 4.4 times the Indian rate.

Now look at the same numbers through the lens of your CFO. For roughly the loaded cost of one Swiss senior pharmacovigilance manager, you can hire four Indian peers at equivalent seniority, give them better office space than anything you have in Basel, and still bank a six-figure annual saving. India produces roughly 2.4 million STEM graduates a year. The time zone overlaps with Europe in the morning and with the US East Coast at end of day, which means a Hyderabad GCC effectively runs a 16-hour workday for the parent company at near-zero coordination overhead. The captive-versus-outsourced debate was settled by 2018. Today's pharma GCCs are built and owned by the multinationals themselves. The parent keeps the IP, the talent and the cost savings simultaneously.

Every CFO presentation to every Big Pharma board in 2024 and 2025 contained the same slide, with a single arrow pointing east. Leadership then flew home and held a "town hall on the future of work" in which the word "India" appeared exactly zero times.

The DACH paradox, and why it's quietly good news

Here is the bit the international press will not write, because outrage sells better than nuance.

The jobs being created in India are precisely the entry- and mid-level functions being eliminated in Western Europe. The jobs being kept in DACH are increasingly the ones that physically cannot leave. German regulatory affairs requiring local market access knowledge. Manufacturing QA at German GMP sites. R&D requiring physical lab presence. Senior commercial leadership built on payer relationships in fluent German. Those roles are, paradoxically, more secure now than they have been for a decade. Precisely because Hyderabad cannot have them.

Wer die Wahl hat, hat die Qual. (Whoever has the choice has the agony.) But at least the DACH professional still has a choice. The career strategy is recognising which list you are on, and acting on it before the announcement, not after.

A short international comparison, for context

UK pharma is hollowing out the same functions at roughly the same speed, with the added theatrical flourish of post-Brexit regulatory friction. The US is doing it harder and faster, with the FDA itself shedding 3,500 staff to political restructuring²⁰. China's domestic biotech market contracted sharply after 2022 and now exports its own pharmacovigilance work, slightly awkwardly, in the same direction the West does. India is the destination of almost everyone's offshoring strategy, including, increasingly, China's.

Nobody in the Western pharma talent market is having a relaxing year. The DACH professional is, statistically, having the least bad one. Take the win.

Five things to do about it

1. Juniors and internship-seekers (DACH and EU candidates, visa-sponsored applicants). Stop sending the same template application to "Pharmacovigilance Associate, entry level" at Big Pharma headquarters in Basel. Those roles, where they still exist, now receive 200 to 400 applications each, many from people with three years of Hyderabad GCC experience. Realistic European entry points in 2026 are CROs, mid-sized German Mittelstand pharma, and specialist biotechs where local language and on-site presence are part of the job description rather than a bonus.

2. Mid-career professionals (2 to 10 years). Audit your CV honestly. Every line that says "case processing", "submission drafting", "data entry" or "report generation" describes a function being moved to India faster than you can update LinkedIn. Pivot the same experience toward what a Bengaluru GCC structurally cannot do: stakeholder management with German authorities, complex cross-functional decisions under regulatory ambiguity, technical leadership of remote teams that already include your Indian colleagues.

3. Senior managers and executives (DACH). You are not being offshored. You are being asked to oversee the offshoring. Many of you will discover, slowly and uncomfortably, that "managing a global capability strategy" is a politically delicate job. The valuable skill in 2027 is designing hybrid Western-Indian operating models that do not collapse the first time a German regulator asks who, specifically, is accountable in Frankfurt. Build that skill in public. Case studies, position papers, conference talks. Recruiters will find you.

4. C-suite. You already know all this. The honest question is whether your succession plan reflects it. The next generation of DACH pharma leadership will be the people who built and ran the Indo-European hybrid operating model, not the ones who supervised its press release.

5. Professionals aged 50 and above. Your structural advantage is the one nobody in Bengaluru can fake. Two decades of institutional memory of how a specific German authority actually responds when an inspection goes sideways. Reframe your CV not as "20 years of regulatory affairs" but as "20 years of avoiding the kind of mistakes that cost an employer eight figures and a press conference". Erfahrung ist der härteste Lehrmeister. (Experience is the hardest teacher.) Tuition fees, in pharma, are paid in Form 483 observations.

For recruiters and TA leaders: the temporary buyer's market

If you are sourcing for DACH pharma roles in 2026, congratulations. You are looking at the deepest applicant pool the European life sciences market has produced since the 2008 financial crisis. Senior regulatory professionals, mid-career pharmacovigilance managers, displaced commercial leaders from companies whose patent cliffs arrived early. Every well-positioned vacancy is generating 200 to 400 applications, and the average quality is high. Enjoy it. It will not last.

The trap is mistaking volume for signal. The candidates whose experience will actually matter in the Indo-European operating model that your CFO is quietly drawing on a whiteboard tend not to be in the bulk of that application pile. They are the ones who already understand the offshoring story, who have built and managed mixed onshore-offshore teams, and who are, almost by definition, already employed somewhere doing exactly that. They have to be sourced actively, not screened reactively. The honest brief in 2026 is not "find me ten qualified candidates fast", because you already have those. It is "find me the three people who can run the function the role will have become by 2028, when 60% of the work the current job description describes is sitting in Hyderabad". Those are different candidates. Hire accordingly, or watch your replacement do it for you next year.

The bottom line. No cliffhanger.

The famous names will be there next year. Probably with fewer Western roles, more layers of internal politics, and another reorganisation announcement written by McKinsey consultants whose own jobs are also being offshored to Bangalore, although that is rarely mentioned in the press release. Your CV does not need to keep visiting them like an unloved relative who has, multiple times, asked you to stop coming round. The hiring is happening exactly where you have not been looking. Some of it is in companies whose names you will need to look up. That is the point.

Your turn

The most useful thing you can do is leave an honest answer to one of these in the comments:

Has your function quietly migrated east in the last three years, and did anyone at your company name it out loud?

What is the most creative euphemism your leadership has used for offshoring?

For 50+ readers: what specific institutional knowledge has saved your employer from a disaster they would never publicly acknowledge?

Recruiters: how many applications are you currently receiving per vacancy, and is the quality matching the volume?

For Career Coaching (Job Search Strategies, Interview Preparation, Salary Negotiation training including tailored scripts), Reverse Recruitment, and CV & LinkedIn rewrite & rebranding services, see morethancareer.de . Follow the More Than Career LinkedIn company page and subscribe to this newsletter. Pharma Bloodbath Part VII is in development. I haven't decided the topic yet. What's the question nobody in your part of the industry is willing to ask out loud? Whichever one draws the sharpest comments wins.

Prost. Und bleibt standhaft. (Cheers. And stay resilient.)

Sources

All footnotes in the article are linked to their sources below. Full numbered reference list:

Sources & References

[1] Flexiple — Latest Employment Stats for Global Capability Centers in India 2026 (2.4M professionals) — https://flexiple.com/global-capability-centers/employment-stats-for-global-capability-centers-in-india

[2] Inductus GCC — Healthcare GCCs in India: Where the World's Pharmaceutical Innovation Actually Happens (45%/60%/54% global share) — https://inductusgcc.com/healthcare-gccs-in-india-where-the-worlds-pharmaceutical-innovation-actually-happens/

[3] Taggd — Pharmacovigilance Hiring Trends in India 2026 (62% surge, +2,200 PV jobs) — https://taggd.in/blogs/pharmacovigilance-hiring-trends-in-india/

[4] AnalyticsIndiaMag — Top 9 GCC Expansions in India in 2025 (AstraZeneca ₹166 crore expansion) — https://analyticsindiamag.com/ai-trends/top-9-gcc-expansions-in-india-in-2025/

[5] Inductus GCC — Healthcare GCCs in India (BMS Hyderabad $100M, 2,000 staff) — https://inductusgcc.com/healthcare-gccs-in-india-where-the-worlds-pharmaceutical-innovation-actually-happens/

[6] BioSpace Layoff Tracker (aggregate Western pharma redundancies 2025) — https://www.biospace.com/biospace-layoff-tracker

[7] PharmExec — Novo Nordisk to Cut 9,000 Jobs in Global Restructuring Effort — https://www.pharmexec.com/view/novo-nordisk-cut-9-000-jobs-global-restructuring-effort

[8] The HR Digest — Why 2025's Pharma Layoffs Are Hitting So Hard (Bayer 12,000 cumulative; 2,000 in Q1 2025) — https://www.thehrdigest.com/why-2025s-pharma-layoffs-are-hitting-so-hard/

[9] Fierce Biotech — Q3 Biopharma Layoffs Hold Steady, Setting 2025 Up to Break Last Year's High (62 rounds Q3) — https://www.fiercebiotech.com/biotech/q3-biopharma-layoffs-hold-steady-setting-2025-break-last-years-high

[10] Pharmuni — Pharmacovigilance Salary Guide 2026 (India ₹8–16L mid; ₹16–32L+ senior) — https://pharmuni.com/2025/11/21/pharmacovigilance-salary-guide/

[11] Glassdoor — Pharmacovigilance Salaries in Bangalore, India (₹493,906 average) — https://www.glassdoor.com/Salaries/bangalore-india-pharmacovigilance-salary-SRCH_IL.0,15_IM1091_KO16,33.htm

[12] Glassdoor — Regulatory Affairs Specialist Salary Germany 2026 (€55K–70K typical range) — https://www.glassdoor.com/Salaries/germany-regulatory-affairs-specialist-salary-SRCH_IL.0,7_IN96_KO8,37.htm

[13] CCRPS — Pharmacovigilance Specialist Salaries 2025 Industry Report (US/Switzerland benchmarks) — https://ccrps.org/clinical-research-blog/pharmacovigilance-specialist-salaries-and-career-growth-2025-industry-report

[14] Payscale — Average Regulatory Affairs Manager Salary in India (₹1,375,790 average) — https://www.payscale.com/research/IN/Job=Regulatory_Affairs_Manager/Salary

[15] ERI SalaryExpert — Regulatory Affairs Manager Salary Germany (€108,158 average; €134,568 senior) — https://www.salaryexpert.com/salary/job/regulatory-affairs-manager/germany

[16] Glassdoor — Regulatory Affairs Salary Switzerland 2025 (CHF 113,000 average; up to CHF 175,000) — https://www.glassdoor.com/Salaries/switzerland-regulatory-affairs-salary-SRCH_IL.0,11_IN226_KO12,30.htm

[17] Biotecnika — Clinical Data Management Salary Trends 2025 (India ₹20–35L senior) — https://www.biotecnika.org/2025/08/clinical-data-management-in-2025-salary-trends-job-opportunities-career-growth/

[18] Payscale — Clinical Data Manager Salary Germany 2026 (€52,080 average) — https://www.payscale.com/research/DE/Job=Clinical_Data_Manager/Salary/fd454bc7/Clinical-Data-Management

[19] Salary.com — Clinical Data Manager Salary United States (February 2026; $144,531 average) — https://www.salary.com/research/salary/benchmark/clinical-data-manager-salary

[20] IntuitionLabs — Pharma & CRO Layoffs 2025–2026: An Industry Analysis (FDA 3,500 dismissals) — https://intuitionlabs.ai/articles/pharma-cro-layoffs-2025-2026-analysis